Evergreen Capital Management LLC Purchases 54,328 Shares of Pfizer Inc. $PFE

Evergreen Capital Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 535,282 shares of the biopharmaceutical company’s stock after purchasing an additional 54,328 shares during the quarter. Evergreen Capital Management LLC’s holdings in Pfizer were worth $13,639,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in PFE. Curio Wealth LLC lifted its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter worth approximately $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer in the second quarter valued at approximately $30,000. True Wealth Design LLC grew its holdings in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Scotiabank started coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $27.88.

Pfizer Price Performance

Pfizer stock opened at $25.68 on Friday. The business’s 50 day simple moving average is $25.35 and its 200 day simple moving average is $24.99. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a market cap of $146.01 billion, a price-to-earnings ratio of 14.93 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.